Discovery of AZD-4144, a potent, direct and selective NLPR3 ...
Sep 10, 2024 · Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases; the drug is currently in phase I trials for cardiorenal disease (NCT06491550, NCT06122714).
Equillium keeps equilibrium in GVHD after Ono no-go | BioWorld
Oct 31, 2024 · Equillium Inc. plans to continue on its own with itolizumab – now the top pipeline priority – as Ono Pharmaceutical Co. Ltd. Is letting expire the option for rights to the monoclonal antibody, designed to target the CD6-ALCAM signaling pathway.
2024 BioWorld Science Year in Review
Dec 31, 2024 · Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more
Biomarker could aid in psychosis diagnosis | BioWorld
Dec 2, 2024 · Researchers at the University of Rochester have described a neuroimaging-based biomarker that could identify individuals with early psychosis, and improved their identification when it was added to a standard neurocognitive diagnostic test. In a group of roughly 160 participants in the Human Connectome Early Psychosis Project, individuals who were in the early stages of psychosis had stronger ...
Appointments and advancements for January 3, 2025 | BioWorld
Jan 3, 2025 · 2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
In the clinic for Jan. 3, 2025 | BioWorld
Jan 3, 2025 · Clinical updates, including trial initiations, enrollment status and data readouts and publications: Neumora, Xgene.
Ketone bodies could clear misfolded proteins in the brain
Dec 5, 2024 · A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become an effective ally in treating Alzheimer’s or preventing the effects of aging on the brain. A group of scientists at the Buck Institute for Research on Aging have studied the role of β-hydroxybutyrate (βHB) as a signaling metabolite of misfolded proteins by interacting ...
In the clinic for Jan 2, 2025 | BioWorld
Jan 2, 2025 · Clinical updates, including trial initiations, enrollment status and data readouts and publications: Axsome, Cocrystal.
Roche reports CD73 inhibitors for cancer | BioWorld
Nov 21, 2024 · A patent from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. describes bicyclic heterocycle 5'-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Glenmark Pharmaceuticals identifies new CBLB inhibitors for cancer
Dec 5, 2024 · Glenmark Pharmaceuticals Ltd. has synthesized substituted biphenyl compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.